




EMLc
ATC codes: [P02CA01](#)

|                          |   |
|--------------------------|---|
| Indication               | Ascariasis <span>ICD11 code: <a href="#">1G33</a></span>  |
| INN                      | Mebendazole   |
| Medicine type            | Chemical agent  |
| List type                | Core (EML) (EMLc)   |
| Formulations             | Oral > Solid > tablet: 100 mg (chewable) ; 500 mg (chewable)  |
| EML status history       | First added in 1977 ( <a href="#">TRS 615</a> )<br>Changed in 1979 ( <a href="#">TRS 641</a> )<br>Changed in 1982 ( <a href="#">TRS 685</a> )<br>Changed in 1987 ( <a href="#">TRS 770</a> )<br>Changed in 1995 ( <a href="#">TRS 867</a> )<br>Changed in 2007 ( <a href="#">TRS 950</a> )<br>Changed in 2011 ( <a href="#">TRS 965</a> ) |
| Sex                      | All   |
| Age                      | Also recommended for children   |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .    |
| Wikipedia                | <a href="#">Mebendazole</a>    |
| DrugBank                 | <a href="#">Mebendazole</a>    |

## Summary of evidence and Expert Committee recommendations

The Committee also decided to delete the square box symbol with mebendazole as all other relevant benzimidazoles are already included in the Model List as individual entries.

